Lb Pharmaceuticals (LBRX) Equity Average (2024 - 2026)

Lb Pharmaceuticals' Equity Average history runs 3 years deep, the most recent figure standing at $340.0 million for Q1 2026.

• In Q1 2026, Equity Average rose 450.71% year-over-year to $340.0 million; the TTM figure through Mar 2026 stood at $340.0 million (up 450.71% YoY), while the FY2025 annual figure was $103.4 million, changed N/A from the prior year.
• Equity Average was $340.0 million for Q1 2026 at Lb Pharmaceuticals, up from $305.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $340.0 million in Q1 2026 to a low of -$96.9 million in Q1 2025.
• Historically, Equity Average has averaged $112.3 million across 3 years, with a median of $105.4 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Equity Average surged 428.77% in 2025, then jumped 450.71% in 2026.
• A 3-year view of Equity Average shows it stood at -$93.0 million in 2024, then soared by 428.77% to $305.8 million in 2025, then grew by 11.2% to $340.0 million in 2026.
• The last three Equity Average figures came in at $340.0 million (Q1 2026), $305.8 million (Q4 2025), and $105.4 million (Q3 2025), per Business Quant data.